Woburn, MA, March 17, 2015 – Newly launched Laurus Synthesis Inc. officially opened its doors yesterday in Woburn, MA, welcoming pharmaceutical and biotech executives to a new, state-of-the-art facility of more than 10,000 square feet. In addition to offices and administrative space, the site features a large portfolio of laboratory space with appropriate air and water treatment capabilities. According to Stuart Needleman, President of Laurus Synthesis Inc., “This facility is ideal for the work we plan to do on site. Even before we made any renovations, the site offered a tremendous amount of lab space for bench chemistry, with fume hoods and other basic requirements in place and ready to use. Coupled with the investments we have made in analytical and process development equipment, we are on track to deliver excellent chemistry services for our clients.”
The Grand Opening event was hosted by Dr. Satyanarayana Chava, Founder and CEO, Laurus Labs, India; Chandrakanth Chereddi, Vice President, Synthesis Business Unit, Laurus Labs, India; Stuart Needleman, President, Laurus Synthesis Inc., Woburn, MA; and Kevin Duffield, Vice President Operations, Woburn, MA. Approximately 50 pharmaceutical and biotech executives attended the event, learning about the company’s capabilities, taking tours of the facilities and networking with their colleagues at an afternoon reception.
Bob Coughlin, President and CEO of the Massachusetts Biotechnology Council (MassBio), welcomed Laurus Synthesis to their Woburn location, situated near the hub and heart of the pharmaceutical and biotechnical community in the Boston area. MassBio is a not-for-profit organization that represents more than 600 biotech companies.
As a U.S. affiliate of Laurus Labs Private Limited, India, Laurus Synthesis Inc. offers specialized laboratory services that assist clients in advancing their concepts to the next milestone including process development, method development, impurity identification services, and route selection for APIs. Laurus Synthesis Inc. also provides intermediates and key starting materials, as well as the collaborative service capabilities of Laurus Labs in India, including smooth technical transition for scale-up and commercialization.
Dr. Satyanarayana Chava stated that, “Working with Laurus Synthesis Inc. here in America is your Passage to India, the theme of today’s event, because this talented scientific team has the full support of Laurus Labs in India, recognized as one of India’s top ten chemistry providers. The synergy of more than 100 of our scientists in India and this new U.S. based team, specifically chosen for their record of innovating breakthrough chemistry, outpaces your previous expectations of pharmaceutical and biotech support from service companies. This launch of Laurus Synthesis Inc. is an example of Laurus Labs’ efforts to offer global services, and now together, we can deliver optimum speed and cost efficiency that you can count on as never before.”
For more information or to arrange an interview, contact Maria Garvey at maria@delfino.com or 914.747.1400. Photos of the event are also available. Please call or email to request them.
About Laurus Synthesis Inc.
Laurus Synthesis Inc. offers specialized laboratory services from a new, state-of-the-art drug development facility in Woburn, Massachusetts. From this site, the company assists clients in advancing their concepts along the best path to their next milestone. Laurus Synthesis chemists and project managers provide process development, method development, impurity identification services and route selection for APIs, as well as intermediates and key starting materials. In addition, a smooth technical transition to the products and services of Laurus Labs for scale-up and commercialization will be available as required. Laurus Synthesis Inc. is a subsidiary of Laurus Labs, one of India’s top ten chemistry providers. For more information, please visit www.laurussynthesis.com.
About Laurus Labs
Based in Visakhapatnam, India, Laurus Labs Private Limited (Laurus) develops and manufactures active pharmaceutical ingredients (API), with a focus on anti-retroviral (ARV) and oncology products. The company supplies its APIs to several Indian and global pharmaceutical companies. In addition to the API business, Laurus offers contract research (chemical, analytical and formulation development) and manufacturing services to generic and innovative pharmaceutical companies. Laurus has world-class infrastructure, consisting of a state-of-the-art R&D and scale-up laboratory in Hyderabad and large-scale manufacturing facilities at Visakhapatnam. These facilities have been accredited by several international regulatory agencies including the US-FDA, UK-MHRA, Australian TGA and Korean FDA. The company has revenues approaching $250 million and currently employs 1,800+ people. For more information, please visit www.lauruslabs.com.
Help employers find you! Check out all the jobs and post your resume.
